|
Shengfeng (Sean) Chen, Ph.D., J.D.Shengfeng Chen specializes in patent matters, and has extensive experience working with start-up companies, international companies, as well as universities and research institutes. His practice focuses on patenting strategy and portfolio development, patent procurement and prosecution, opinion work, intellectual property due diligence, freedom-to-operate and patent landscape analysis, patent validity analysis.
|
Life Sciences
In life sciences arena, Shengfeng has been serving clients in various areas including antibody-based therapeutics, molecular diagnostics, enzyme technologies, next-generation nucleic acid sequencing technologies, genetically modified organisms, protein and peptide pharmaceuticals, and small molecule pharmaceuticals. In the past, he has provided legal representation to companies conducting half a billion Phase III clinical trials, and has helped many early stage companies to develop patenting strategies and portfolios that support the companies' objectives and provide negotiation leverage.
Most recently, Shengfeng provides global IP strategies to a cancer therapeutics company, and successfully obtained key platform patent portfolio for the client.
Hi-Tech and Smart Tech
In hi-tech and smart tech arena, Shengfeng routinely assists companies in strategic patent portfolio development and management. Shengfeng provides a highly collaborative approach to patenting hi-tech and smart tech inventions, particularly for technologies in a crowded patent landscape, through proactively working with engineers and in-house IP managers.
Most recently, Shengfeng represents a global technology company in developing and managing US patent portfolio relating to their core businesses, including interface devices, smart IoT systems, and smart medicine and engineering integration.
In life sciences arena, Shengfeng has been serving clients in various areas including antibody-based therapeutics, molecular diagnostics, enzyme technologies, next-generation nucleic acid sequencing technologies, genetically modified organisms, protein and peptide pharmaceuticals, and small molecule pharmaceuticals. In the past, he has provided legal representation to companies conducting half a billion Phase III clinical trials, and has helped many early stage companies to develop patenting strategies and portfolios that support the companies' objectives and provide negotiation leverage.
Most recently, Shengfeng provides global IP strategies to a cancer therapeutics company, and successfully obtained key platform patent portfolio for the client.
Hi-Tech and Smart Tech
In hi-tech and smart tech arena, Shengfeng routinely assists companies in strategic patent portfolio development and management. Shengfeng provides a highly collaborative approach to patenting hi-tech and smart tech inventions, particularly for technologies in a crowded patent landscape, through proactively working with engineers and in-house IP managers.
Most recently, Shengfeng represents a global technology company in developing and managing US patent portfolio relating to their core businesses, including interface devices, smart IoT systems, and smart medicine and engineering integration.
Education
University of California Hastings College of Law, J.D. (cum laude)
University of California, Berkeley, Postdoctoral Training (Chemistry)
Rutgers University, New Brunswick, New Jersey, Ph.D. (Biophysics)
Peking University, B.S. (Chemistry)
Admissions
State Bar of California (2008)
U.S. Patent & Trademark Office (2005)
University of California Hastings College of Law, J.D. (cum laude)
University of California, Berkeley, Postdoctoral Training (Chemistry)
Rutgers University, New Brunswick, New Jersey, Ph.D. (Biophysics)
Peking University, B.S. (Chemistry)
Admissions
State Bar of California (2008)
U.S. Patent & Trademark Office (2005)
Publications
- Pathways to Patents: Applying the Written Description Requirement Doctrine to Patents on Biological Pathways. 30 Hastings Communication and Entertainment Law Journal 559 (2008).
- Signatures of protein-DNA recognition in crystal structures of free DNA binding sites. (2009).
- Structural genomics of minimal organisms and protein fold space. Journal of Structural and Functional Genomics. 6, 63-70 (2005).
- Structure of the hypothetical Mycoplasma protein, MPN555, suggests a chaperone function. Acta Crystallographica D. 61, 1343-1347 (2005).
- Crystal Structure of methenyltetrahydrofolate synthetase from Mycoplasma pneumoniae (GI: 13508087) at 2.2 Å resolution. Proteins 56, 839-843 (2004).
- Structural and functional characterization of a novel archaeal nuclease/phosphodiesterase. Journal of Biological Chemistry. 279, 31854-31862 (2004).
- Crystal Structure of a Protein Associated with Cell Division from Mycoplasma pneumoniae (GI: 13508053): a Novel Fold with a Conserved Sequence Motif. Proteins 55, 785-91 (2004).
- Structure-based functional inference in structural genomics. Journal of Structural and Functional Genomics Vol. 4, Issue 2-3, 129-135 (2003).
- Structure of the hypothetical protein AQ_1354 from Aquifex aeolicus. Acta Crystallographica D. 59, 1219-1223 (2003).
- Checking nucleic acid crystal structures. Acta Crystallographica D. 57, 813-828 (2001).
- Indirect readout of DNA sequence at the primary-kink site in the CAP-DNA complex: alteration of DNA binding specificity through alteration of DNA kinking. Journal of Molecular Biology. 314, 75-82 (2001).
- Indirect readout of DNA sequence at the primary-kink site in the CAP-DNA complex: DNA binding specificity based on energetics of DNA kinking. Journal of Molecular Biology. 314, 63-74 (2001).